Kerendia 20 Mg Tablet (Finerenone)

Description

Introduction

Kerendia 20 Mg Tablet (Finerenone) contains finerenone, a non-steroidal mineralocorticoid receptor antagonist. Finerenone is used in selected adults with chronic kidney disease associated with type 2 diabetes. It may help reduce the risk of worsening kidney function and certain cardiovascular complications.

Treatment requires medical supervision because kidney function, blood potassium and other medicines influence its safety and suitability. Finerenone forms part of a broader management plan rather than replacing existing diabetes or cardiovascular care.

What Is It?

Kerendia 20 Mg Tablet is an oral medicine containing 20 mg of finerenone per tablet. It belongs to a class of medicines called mineralocorticoid receptor antagonists.

Finerenone is not primarily a blood glucose-lowering treatment. Its role concerns kidney and cardiovascular protection in appropriately selected patients. The 20 mg strength does not establish the correct prescribed dose for every individual.

How Does It Work?

Finerenone blocks mineralocorticoid receptors involved in the effects of hormones such as aldosterone. Excessive receptor activity contributes to processes associated with kidney and cardiovascular damage.

Blocking these receptors helps limit harmful activity. However, finerenone can also increase blood potassium, making regular laboratory monitoring essential during treatment.

Common Uses

Finerenone is used in adults with chronic kidney disease associated with type 2 diabetes. Its clinical role includes reducing certain kidney and cardiovascular risks.

• Reducing the risk of worsening kidney function.
• Reducing certain serious cardiovascular complications.
• Lowering the risk of hospitalisation for heart failure in suitable patients.

Suitability depends on clinical assessment. Finerenone does not replace prescribed diabetes medicines or treat every type of kidney disease.

Available Strengths

This family is available in 10 mg, 20 mg.

Key Features

• Active ingredient: finerenone.
• Strength: 20 mg per tablet.
• Form: oral tablet.
• Class: non-steroidal mineralocorticoid receptor antagonist.
• Use: selected adults with diabetic chronic kidney disease.
• Monitoring: kidney function and blood potassium.

Benefits

Potential benefits depend on individual circumstances and appropriate clinical selection.

• Kidney protection: may slow deterioration in kidney function.
• Cardiovascular protection: may reduce certain serious cardiovascular risks.
• Heart failure: may reduce related hospitalisations.
• Targeted mechanism: blocks mineralocorticoid receptor activity.
• Oral administration: allows prescribed tablet-based treatment.

Benefits must be weighed against adverse effects and monitoring requirements.

Possible Side Effects

Finerenone can cause adverse effects, including changes detected through blood tests.

• Hyperkalaemia: increased blood potassium, potentially serious.
• Low blood pressure: may cause dizziness or faintness.
• Low sodium: may occur in some patients.
• Other symptoms: persistent or unusual reactions require assessment.

Muscle weakness, unusual heartbeat, severe dizziness or fainting may indicate a serious problem. Seek prompt medical attention for concerning symptoms, and emergency assistance for severe reactions.

Precautions

• Potassium: elevated levels may prevent or interrupt treatment.
• Kidney function: assessment is required before and during treatment.
• Adrenal insufficiency: finerenone must not be used in people with this condition.
• Liver problems: disclose existing liver disease.
• Allergies: report previous reactions to medicines.
• Monitoring: attend scheduled blood tests and clinical reviews.

Never independently adjust treatment in response to laboratory results.

Additional Precautions

• Pregnancy: inform the clinician if pregnant, planning pregnancy or becoming pregnant.
• Breastfeeding: avoid breastfeeding during treatment and for one day after the final dose.
• Potassium supplements: discuss use before combining with finerenone.
• Salt substitutes: potassium-containing products may increase risk.
• Grapefruit: avoid grapefruit and grapefruit juice during treatment.
• Other conditions: disclose relevant medical history before treatment.

Storage Instructions

• Keep medicine in its original container, tightly closed.
• Store at room temperature, away from excessive heat and moisture.
• Avoid bathrooms and other persistently humid locations.
• Keep out of reach of children and pets.
• Follow the supplied packaging’s storage and expiry instructions.
• Ask a pharmacist how to dispose of unwanted medicine safely.

How to Take

Finerenone is taken orally according to an individually prescribed regimen. Kidney function and potassium measurements influence treatment decisions.

• Follow the treating clinician’s prescription instructions.
• Finerenone is generally taken once daily.
• It may be taken with or without food.
• Take it at approximately the same time each day.
• If a dose is missed, take it only when remembered that day.
• Otherwise, skip the missed dose; never double doses.
• Consult a pharmacist about swallowing difficulties or administration questions.

Drug Interactions

Finerenone may interact with medicines, supplements and herbal products. Some combinations increase finerenone exposure or blood potassium.

• Clarithromycin: an important interacting antibiotic.
• Antifungals: ketoconazole and itraconazole may interact.
• Antivirals: ritonavir-containing treatments require particular caution.
• Potassium supplements: may increase hyperkalaemia risk.
• St John’s wort: may affect finerenone exposure.
• Grapefruit products: may alter medicine metabolism.

Provide a complete medication list to the treating clinician or pharmacist. Some combinations must be avoided rather than merely monitored.

Why Choose This Product?

• Contains the identified active ingredient finerenone.
• Provides a stated strength of 20 mg per tablet.
• Offers an oral tablet presentation.
• Contains an ingredient with an established therapeutic role in selected adults with diabetic chronic kidney disease.
• Requires individual prescribing and ongoing safety monitoring.

Selection should reflect clinical suitability, not strength alone.

Frequently Asked Questions (FAQs)

1. What is Kerendia 20 Mg Tablet?

It is an oral tablet containing 20 mg of finerenone, a mineralocorticoid receptor antagonist.

2. What is finerenone used for?

It helps reduce certain kidney and cardiovascular risks in selected adults with chronic kidney disease associated with type 2 diabetes.

3. Does finerenone lower blood glucose?

It is not primarily a glucose-lowering medicine and does not replace prescribed diabetes treatment.

4. Why is potassium monitoring necessary?

Finerenone can increase blood potassium, sometimes dangerously. Blood tests help identify changes requiring medical attention.

5. Can finerenone be taken with food?

Yes. Finerenone is generally taken with or without food, following prescription instructions.

6. What if a dose is missed?

Take it if remembered on the same day. Otherwise, skip it and continue the usual schedule without doubling.

7. Can finerenone interact with medicines?

Yes. Certain antibiotics, antifungals, antivirals, potassium products and herbal preparations may cause important interactions.

8. Is finerenone safe during pregnancy?

Finerenone may pose risks during pregnancy. Seek medical advice immediately if pregnancy occurs or is planned.

9. Can everyone with kidney disease take finerenone?

No. The diagnosis, kidney function, potassium concentration and other medicines determine suitability.

10. What monitoring is needed?

Regular assessment generally includes blood potassium, kidney function and treatment response, according to the clinician’s instructions.

Related Products

• Kerendia 10 Mg Tablet (Finerenone)
• Kerendia 20 Mg Tablet (Finerenone)
• Ambrisentan 10 mg Australia
• Riociguat 0.5 Mg Australia
• Atorvastatin 80 mg Australia
• Bosentan 125 Mg Australia